ETF Series Solutions's Loncar China BioPharma ETF (CHNA) has disclosed 66 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2023-08-31. The current portfolio value is calculated to be $4.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 0%.
Loncar China BioPharma ETF (CHNA)'s
Total Assets is $4.16 Mil , Total Liabilities is $3,620.00 , Net Assets is $4.16 Mil.
In Loncar China BioPharma ETF (CHNA)'s current portfolio as of 2023-08-31, the top 5 holdings are
AIM Vaccine Co Ltd (HKSE:06660), Legend Biotech Corp (LEGN), Wuxi AppTec Co Ltd (HKSE:02359), Sinopharm Group Co Ltd (HKSE:01099) and BeiGene Ltd (BGNE),
not including call and put options.
Loncar China BioPharma ETF (CHNA) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Loncar China BioPharma ETF (CHNA), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Loncar China BioPharma ETF (CHNA), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Loncar China BioPharma ETF.